NCT01486368 - A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 26, 2012

Primary Completion Date

April 27, 2014

Study Completion Date

February 13, 2015

Conditions

Malignant Pleural Mesothelioma

Interventions

DRUG

PF-03446962

PF-03446962 will be administered by IV infusion every 2 weeks (q2w). A cycle will be 2 weeks in duration and include one administration of PF-03446962.

Trial Locations (7)

T6G 1Z2

Cross Cancer Institute, Edmonton

V3V 1Z2

BCCA - Fraser Valley Cancer Centre, Surrey

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

R3E 0V9

CancerCare Manitoba, Winnipeg

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K1H 8L6

Ottawa Health Research Institute - General Division, Ottawa

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto